GlassScriptPhysician profile
Jaron Evan Mark
NPI 1073888319
$5,883.72
in general payments reported to CMS, 2019-2025
35 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $244 · 2021: $386 · 2022: $756 · 2023: $1,296 · 2024: $2,488 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,975 · Consulting Fee: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,974.80 |
| Consulting Fee | $1,375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,069.18 | 2020-2025 | Lynparza, Enhertu, Tagrisso |
| Glaxosmithkline, LLC. | $483.01 | 2020-2024 | Jemperli, Shingrix, Zejula |
| Myriad Genetic Laboratories, INC. | $432.51 | 2021-2024 | Mychoice Cdx, Precisetumor |
| Eisai INC. | $408.81 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $351.89 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $286.06 | 2020-2023 | Tivdak |
| Tempus Ai, INC | $252.72 | 2024 | |
| Abbvie INC. | $125.45 | 2024-2025 | |
| Tesaro, INC. | $124.96 | 2019 | |
| Sobi, INC | $111.54 | 2022-2025 | |
| Janssen Biotech, INC. | $102.38 | 2021-2025 | Erleada, Darzalex, Balversa |
| Amgen INC. | $94.60 | 2021-2022 | |
| Pfizer INC. | $94.19 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $92.77 | 2022-2023 | Xpovio |
| Incyte Corporation | $78.45 | 2021-2025 | Jakafi, Monjuvi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $78.10 | 2022 | |
| Intuitive Surgical, INC. | $76.61 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.94 | 2022-2024 | Iclusig, Ninlaro |
| Daiichi Sankyo INC. | $68.55 | 2022-2025 | Datroway, Enhertu |
| Genzyme Corporation | $61.93 | 2021-2023 | |
| Genentech USA, INC. | $55.63 | 2023-2024 | Perjeta, Phesgo, Columvi |
| Servier Pharmaceuticals LLC | $43.05 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.99 | 2023-2024 | |
| Smith+Nephew, INC. | $41.19 | 2024 | Stravix Pl |
| Mirati Therapeutics, INC. | $40.68 | 2023 | Krazati |
| Jazz Pharmaceuticals INC. | $33.26 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $25.94 | 2024 | |
| Astellas Pharma US INC | $23.73 | 2025 | Xtandi |
| Stemline Therapeutics INC. | $20.52 | 2025 | Orserdu |
| Dova Pharmaceuticals | $20.02 | 2021 | |
| Taiho Oncology, INC. | $19.41 | 2023 | |
| Agios Pharmaceuticals, INC. | $18.49 | 2023 | Pyrukynd |
| Meditrina | $17.27 | 2025 | |
| Baxter Healthcare | $14.21 | 2023 | Tisseel |
| Clovis Oncology, INC. | $1.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaron Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.